- Published at
- by sec.gov
neutral
neutral
NuGenerex Immuno-Oncology, Inc.
1`b)x8EB&fB܀s%&gJ(Xm`Gks>DwnB`>;UN%ܣ,v%|НtY,E>Zu+W柄.gRL8k✳⼄73Tq xR$T9Q9mq9!w1$!is,MT>Xf1Ҳ]xr g i"Dfm#t;*iAcr#"mWb{Iiʴ3kyiU&jL2qD0]LkMkSOCW!џv]6...
News for NuGenerex Immuno-Oncology, Inc. (NUGX)
- Published at
- by marketscreener.com
positivepositiveGenerex Biotechnology : Material Event (Form 8-K)
Other Events. On July 22, 2021, Generex Biotechnology Corporation on behalf of itself and its subsidiary NuGenerex Immuno-Oncology, Inc. entered into a Quality Agreement with... | July 23, 2021- Published at
- by financialpost.com
mixedmixedNuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) — NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation…- Published at
- by marketscreener.com
mixedmixedNuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
Ii-Key Immunotherapeutic Vaccine TechnologyIi-Key-SARS-CoV-2 Vaccine Market Potential & International ContractsMarket Potential for AE37 Immunotherapeutic Vaccine for breast, prostate, and... | June 22, 2021- Published at
- by globenewswire.com
mixedmixedNuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
Ii-Key Immunotherapeutic Vaccine TechnologyIi-Key-SARS-CoV-2 Vaccine Market Potential & International ContractsMarket Potential for AE37 (Ii-Key-HER2)...- Published at
- by financialpost.com
mixedmixedGenerex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets
MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative…- Published at
- by thestreet.com
positivepositiveGenerex Posts Recording Of May 6 Shareholder Conference Call Highlighting Its Ii-Key COVID Complete Vaccine™ And Its Go-Forward Plans For Revenue Producing Assets
Update on Ii-Key-SARS-CoV-2 vaccine program Appointment of Dr. Craig Eagle to be Chairman of the Board of NuGenerex Immuno-Oncology Inc. pending board- Published at
- by thestreet.com
mixedmixedGenerex Biotechnology Announces Shareholder Conference Call Scheduled For Thursday May 6, 2021
MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) ("Generex or the "Company"), an innovative and integrated